Advanced Medical Solutions (AMS) announces Board member Liz Shanahan as next Chair of its Board of Directors

– UK, Winsford –  Advanced Medical Solutions Group plc (LON: AMS), the world-leading specialist in tissue-healing technologies, today announced the appointment of current Non-Executive Director Liz Shanahan as Chair of the Board of Directors effective on 1 January 2024, to succeed Peter Allen who is stepping down after ten years with the Group.

“We look forward to welcoming Liz as Chair in January. Her many years of life sciences experience and significant contribution to AMS since joining as a Non-Executive Director made her the ideal candidate to now lead the Board from 2024 onwards. Having worked with Liz for the past years, I know the benefit, insight and strategic guidance Liz will bring as we work closely together to execute the AMS growth strategy,” said Chris Meredith.

About Liz Shanahan

Liz Shanahan is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organizations on their communications. She is currently a Non-Executive Director of AIM-listed businesses Inspiration Healthcare Group plc (LON: IHC) and Celadon Pharmaceuticals plc (LON: CEL) and was previously Non-Executive Director of UDG Healthcare plc until its £2.8 billion takeover in August 2021. Between 2011 and 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London, and a member of the organization’s Innovations Advisory Board. Alongside her Board appointments, she is a business advisor and Executive coach.

Liz Shanahan said: “I am delighted to assume the role of Chair of AMS during this pivotal time for the business, with entry into new markets and product categories on the near horizon. It is clear to me that the business has the ambition and capabilities to execute on the attractive long-term growth opportunities in its markets. This is underpinned by the team’s drive and expertise. I look forward to working with Chris Meredith, the Executive team and the rest of the Board, for the benefit of all our stakeholders.”

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, hemostats, internal fixation devices, and internal sealants, which it markets under its brands LiquiBand, RESORBA, LiquiBandFix8, and Seal-G. AMS also supplies wound care dressings such as silver alginates, alginates, and foams through its ActivHeal brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of wound care and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexion, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic, and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees.

SOURCE: https://www.admedsol.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.